Affiliation: Institut Gustave Roussy
- Should transdermal rather than oral estrogens be used in menopausal hormone therapy? A reviewAgnes Fournier
Inserm U1018, Institut Gustave Roussy, 39 rue Camille Desmoulins, F 94805 Villejuif, France
Menopause Int 16:23-32. 2010..The issue of the route of administration of MHT should remain an active area of research as part of an attempt to identify treatment modalities that would have the least potential for exerting adverse effects...
- Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3N prospective cohort: true associations or bias?Sophie Morois
INSERM, CESP Centre for research in Epidemiology and Population Health, UMRS 1018, Team 9, Institut Gustave Roussy, Espace Maurice Tubiana, 94805 Villejuif, Cedex, France
Eur J Epidemiol 27:439-52. 2012..06. Our data suggest a complex relationship between MHT use, colorectal tumour risk and screening strategies, which deserves further investigations in other settings...
- Risk of osteoporotic fractures after discontinuation of menopausal hormone therapy: results from the E3N cohortPierre Engel
INSERM, Centre for research in Epidemiology and Population Health, Team 9, Nutrition, Hormones and Women s Health Team, Institut Gustave Roussy, University Paris Sud, UMRS 1018, Villejuif, France
Am J Epidemiol 174:12-21. 2011..These findings, which relied on a number of MHT combinations, suggested that such therapies should be used for 5 years or more for reducing risk of fracture after treatment discontinuation...